Catalyst Pharmaceuticals Stock Alpha and Beta Analysis
| CPRX Stock | USD 15.45 0.11 0.71% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Catalyst Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Catalyst Pharmaceuticals over a specified time horizon. Remember, high Catalyst Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Catalyst Pharmaceuticals' market risk premium analysis include:
Beta 1.35 | Alpha (0.05) | Risk 2.25 | Sharpe Ratio (0.02) | Expected Return (0.04) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Catalyst |
Catalyst Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Catalyst Pharmaceuticals market risk premium is the additional return an investor will receive from holding Catalyst Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Catalyst Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Catalyst Pharmaceuticals' performance over market.| α | -0.05 | β | 1.35 |
Catalyst Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Catalyst Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Catalyst Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Catalyst Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Catalyst Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Catalyst Pharmaceuticals shares will generate the highest return on investment. By understating and applying Catalyst Pharmaceuticals stock market price indicators, traders can identify Catalyst Pharmaceuticals position entry and exit signals to maximize returns.
Catalyst Pharmaceuticals Return and Market Media
The median price of Catalyst Pharmaceuticals for the period between Fri, Mar 15, 2024 and Thu, Jun 13, 2024 is 15.81 with a coefficient of variation of 3.64. The daily time series for the period is distributed with a sample standard deviation of 0.57, arithmetic mean of 15.76, and mean deviation of 0.48. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Investors in Catalyst Pharmaceuticals have seen strong returns of 271 percent over the past three years | 03/22/2024 |
2 | Acquisition by David Tierney of 25000 shares of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3 | 04/08/2024 |
3 | Catalyst Pharmaceutical Reports Next Week Wall Street Expects Earnings Growth | 05/01/2024 |
4 | Catalyst Pharmaceuticals First Quarter 2024 Earnings EPS Misses Expectations | 05/10/2024 |
5 | Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating - Investors Business Daily | 05/14/2024 |
6 | PTC Therapeutics rallies 18 percent on EU authorization update for Translarna | 05/20/2024 |
7 | FDA approves higher dose of Catalysts LEMS drug | 05/30/2024 |
8 | Disposition of 5333 shares by Harper Molly of Catalyst Pharmaceuticals at 16.304 subject to Rule 16b-3 | 06/03/2024 |
9 | Disposition of 17323 shares by Daly Richard J of Catalyst Pharmaceuticals at 15.975 subject to Rule 16b-3 | 06/04/2024 |
10 | Catalyst Pharmaceuticals, Inc.s institutional investors lost 3.2 percent last week but have benefitted from longer-term gains | 06/05/2024 |
11 | Insider Transaction Richard J Daly Sells 276K Worth Of Catalyst Pharmaceuticals Shares | 06/06/2024 |
12 | Catalyst Pharmaceuticals executive sells shares worth over 1.29 million | 06/07/2024 |
13 | Insider Transaction Jeffrey Del Carmen Sells 121K Worth Of Catalyst Pharmaceuticals Shares | 06/12/2024 |
About Catalyst Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Catalyst or other stocks. Alpha measures the amount that position in Catalyst Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 17.15 | 17.79 | 49.05 | 44.0 | PTB Ratio | 3.38 | 6.4 | 4.61 | 4.38 |
Catalyst Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Catalyst Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Catalyst Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Catalyst Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Catalyst Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Catalyst Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.